Yifan Pharmaceutical: Some products are selected for the national centralized drug procurement and follow-up procurement.

Yifan Medicine announced that its wholly-owned subsidiaries, Suizhou Yifan Pharmaceutical and Liaoning Yifan Pharmaceutical, participated in the declaration for the continuation of the purchase of products whose agreements in the first to eighth batches of national organized procurement have expired. The company's products, Lafaxidene tablets and Lorazepam hydrochloride injection concentrate, were selected for purchase. The purchase period for Lorazepam hydrochloride injection concentrate is until December 31, 2028. As of the disclosure date, the selected products have a small contribution to revenue and a minimal short-term impact on performance. If contracts are signed and implemented, it will be beneficial in enhancing the accessibility and brand influence of the products. There are uncertainties in the subsequent signing of purchase contracts and sales execution.